ATAI Life Sciences announces close of $24 million convertible note financing round and welcomes Jason Camm of Thiel Capital to Board of Directors
ATAI Life Sciences announces close of $24 million convertible note financing round and welcomes Jason Camm of Thiel Capital to Board of Directors
04/23/20, 4:36 PM
Location
new yorkMoney raised
$24 million
ATAI Life Sciences ("ATAI" or the "Company"), a global biotechnology company builder founded by Christian Angermayer that envisions an end to mental illnesses, today announced the close of a $24 million convertible note financing round. Despite market turmoil caused by the COVID-19 pandemic, the round saw strong support from both new and existing investors.
Company Info
Location
new york, new york, united states
Additional Info
Founded by visionary entrepreneur Christian Angermayer, ATAI Life Sciences AG is a global biotech platform and company builder working to address significant unmet medical needs rooted in a lack of innovation in neuropsychiatry. Based in Berlin, London and New York, its vision is to cure mental health disorders, enabling people to live healthier and happier lives.